X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
MYLAN
Dec-14
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,8383,830-   
Low Rs2,6372,699-   
Sales per share (Unadj.) Rs354.21,311.3-  
Earnings per share (Unadj.) Rs39.8158.0-  
Cash flow per share (Unadj.) Rs42.9254.3-  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.9651.9-  
Shares outstanding (eoy) m84.70378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x9.12.5 367.1%   
Avg P/E ratio x81.420.7 393.9%  
P/CF ratio (eoy) x75.512.8 588.2%  
Price / Book Value ratio x13.75.0 272.8%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2161,235,346 22.2%   
No. of employees `0004.725.0 18.8%   
Total wages/salary Rs m4,8300-   
Avg. sales/employee Rs Th6,387.019,846.6 32.2%   
Avg. wages/employee Rs Th1,028.30-   
Avg. net profit/employee Rs Th717.12,390.8 30.0%   
INCOME DATA
Net Sales Rs m30,000496,164 6.0%  
Other income Rs m728-2,892 -25.2%   
Total revenues Rs m30,728493,272 6.2%   
Gross profit Rs m4,190123,398 3.4%  
Depreciation Rs m26336,441 0.7%   
Interest Rs m021,402 0.0%   
Profit before tax Rs m4,65562,663 7.4%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7442,635 66.2%   
Profit after tax Rs m3,36859,771 5.6%  
Gross profit margin %14.024.9 56.2%  
Effective tax rate %37.54.2 890.9%   
Net profit margin %11.212.0 93.2%  
BALANCE SHEET DATA
Current assets Rs m16,742436,194 3.8%   
Current liabilities Rs m7,202341,017 2.1%   
Net working cap to sales %31.819.2 165.8%  
Current ratio x2.31.3 181.7%  
Inventory Days Days5278 66.4%  
Debtors Days Days21107 19.4%  
Net fixed assets Rs m8,635114,786 7.5%   
Share capital Rs m84717,546 4.8%   
"Free" reserves Rs m19,2220-   
Net worth Rs m20,069246,643 8.1%   
Long term debt Rs m10368,460 0.0%   
Total assets Rs m30,038993,454 3.0%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.00.5 200.0%   
Return on assets %11.28.2 137.2%  
Return on equity %16.824.2 69.3%  
Return on capital %25.513.6 186.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,36065,221 3.6%  
From Investments Rs m3,008-51,435 -5.8%  
From Financial Activity Rs m-5,108-17,186 29.7%  
Net Cashflow Rs m260-3,400 -7.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare GSK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: DR. DATSONS LABS  SUVEN LIFE  PANACEA BIOTECH  VENUS REMEDIES  BIOCON LTD  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS